Stock DNA
Pharmaceuticals & Biotechnology
SEK 833 Million (Micro Cap)
NA (Loss Making)
NA
0.00%
-1.31
-999,999.00%
2.26
Revenue and Profits:
Net Sales:
14 Million
(Quarterly Results - Dec 2025)
Net Profit:
-61 Million
Total Returns (Price + Dividend) 
Company does not have enough history
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
125.60%
EBIT Growth (5y)
-224.94%
EBIT to Interest (avg)
0
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
0
Sales to Capital Employed (avg)
0
Tax Ratio
Tax Ratio is Negative%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
0
ROE (avg)
0
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
1.62
EV to EBIT
-1.03
EV to EBITDA
-1.03
EV to Capital Employed
-1.48
EV to Sales
37.87
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
Negative Capital Employed
ROE (Latest)
-35.91%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bearish
RSI
No Signal
No Signal
Bollinger Bands
Bearish
Bearish
Moving Averages
Mildly Bullish (Daily)
KST
Mildly Bearish
Dow Theory
Mildly Bullish
Mildly Bearish
OBV
No Trend
No Trend
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Quarterly Results Snapshot (Consolidated) - Dec'25 - QoQ
Dec'25
Sep'25
Change(%)
Net Sales
13.60
9.70
40.21%
Operating Profit (PBDIT) excl Other Income
-61.10
-42.50
-43.76%
Interest
0.00
0.00
Exceptional Items
0.00
0.00
Consolidate Net Profit
-61.20
-40.70
-50.37%
Operating Profit Margin (Excl OI)
-4,542.30%
-4,429.50%
-11.28%
USD in Million.
Net Sales
QoQ Growth in quarter ended Dec 2025 is 40.21% vs -71.55% in Sep 2025
Consolidated Net Profit
QoQ Growth in quarter ended Dec 2025 is -50.37% vs 16.08% in Sep 2025
Annual Results Snapshot (Consolidated) - Dec'25
Dec'25
Dec'24
Change(%)
Net Sales
57.50
4.60
1,150.00%
Operating Profit (PBDIT) excl Other Income
-195.80
-167.60
-16.83%
Interest
0.00
8.70
-100.00%
Exceptional Items
0.00
1.20
-100.00%
Consolidate Net Profit
-184.00
-168.00
-9.52%
Operating Profit Margin (Excl OI)
-3,448.40%
-36,884.50%
3,343.61%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2025 is 1,150.00% vs -23.33% in Dec 2024
Consolidated Net Profit
YoY Growth in year ended Dec 2025 is -9.52% vs 21.90% in Dec 2024






